<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01400048</url>
  </required_header>
  <id_info>
    <org_study_id>Aloe Vera AVH200</org_study_id>
    <nct_id>NCT01400048</nct_id>
  </id_info>
  <brief_title>Aloe Vera in Irritable Bowel Syndrome</brief_title>
  <official_title>Aloe Vera Versus Placebo for Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Calmino group AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to study the effect of aloe vera in the treatment of IBS
      patients in a randomized, double-blind placebo controlled study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is limited knowledge of the IBS pathophysiology, absence of biological markers and
      therefore few effective treatment options. IBS therefore contributes to difficulties in the
      management of the patients. Aloe vera has a long association with herbal medicine, from the
      Ebers Papyrus from 16th century BCE. It is alleged to be effective in treatment of wounds, to
      improve blood glucose levels in diabetics, and it may reduce symptoms and inflammation in
      patients with ulcerative colitis. Evidence of the effects of aloe vera in the treatment of
      IBS, is however limited and contradictory.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IBS symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Aloe vera effervescent tablet (AVH200)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aloe vera effervescent tablet (AVH200)</intervention_name>
    <description>250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®</description>
    <arm_group_label>Aloe vera effervescent tablet (AVH200)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>60mg Ascorbic acid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IBS according to the Rome III criteria

          -  Adults

        Exclusion Criteria:

          -  other GI disorders

          -  other medical conditions

          -  were pregnancy or breast-feeding

          -  food allergy or intolerance to other than lactose

          -  ongoing intake of aloe vera products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Simrén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Internal medicine, Sahlgrenska UH, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magnus Simrén, Professor</last_name>
    <phone>+46 31 342 81 07</phone>
    <email>magnus.simren@medicine.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stine Storsrud, PhD</last_name>
    <phone>+46 31 342 81 07</phone>
    <email>stine.storsrud@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mag-tarmlab, Dept of Internal Medicine, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisela Ringstrom, PhD</last_name>
      <phone>+46 31 342 81 07</phone>
      <email>gisela.ringstrom@vgregion.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Magnus Simrén</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

